Commonwealth Equity Services
RCKT icon

Commonwealth Equity Services’s Rocket Pharmaceuticals RCKT Stock Holding History

Commonwealth Equity Services’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
+29,520
New +$98.2K ﹤0.01% 4253

Other funds holding RCKT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Commonwealth Equity Services's RCKT Position: Q2 2026 in Review

Commonwealth Equity Services opened a new position in Rocket Pharmaceuticals (RCKT) in Q2 2026: 29,520 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #4253 among its holdings.

33 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Commonwealth Equity Services held 29,520 shares of Rocket Pharmaceuticals worth $101K as of Q2 2026.
  • Rocket Pharmaceuticals was a new Commonwealth Equity Services position in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4253 holding.
  • 33 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.